REGULATED PRESS RELEASE published on 03/26/2026 at 07:30, 4 months 19 days ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY Biophytis SA participated in NVIDIA GTC conference to advance AI-driven drug discovery in longevity in collaboration with LynxKite Technologies and Nebius, positioning them at the forefront of innovation in the $1.5 trillion longevity market Longevity Biophytis SA AI-driven Drug Discovery NVIDIA GTC Conference LynxKite Technologies
PRESS RELEASE published on 03/26/2026 at 07:30, 4 months 19 days ago Annual results 2025 Netgem (Euronext Growth: ALNTG) reports 2025 annual results with €31.7M revenue, €1.9M operating income, and €0.05 dividend. Focus on recurring revenues and product strategy for hesitant telecom market Revenue Dividend Telecom Netgem ALNTG
PRESS RELEASE published on 03/26/2026 at 07:29, 4 months 19 days ago Hapag-Lloyd publishes 2025 annual report and proposes dividend of EUR 3.00 per share Hapag-Lloyd publishes 2025 annual report, proposes EUR 3.00 dividend per share. Earnings slightly below prior year, 2026 outlook uncertain due to geopolitical factors Dividend Proposal Hapag-Lloyd Earnings Geopolitical Uncertainty 2025 Annual Report
PRESS RELEASE published on 03/26/2026 at 07:29, 4 months 19 days ago Mister Spex Closes First Transformation Phase with Significant Earnings Improvement Mister Spex SE reports significant earnings improvement in 2025, achieving structural margin expansion and store profitability. Focus shifts to enhancing infrastructure and operational efficiency in 2026 Operational Efficiency Mister Spex SE Earnings Improvement Revenue Quality Infrastructure Modernisation
PRESS RELEASE published on 03/26/2026 at 07:29, 4 months 19 days ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY Biophytis announces participation at NVIDIA GTC conference, showcasing AI-driven drug discovery collaborations with LynxKite and Nebius to revolutionize longevity innovation Biophytis AI-driven Drug Discovery LynxKite NVIDIA GTC Longevity Innovation
PRESS RELEASE published on 03/26/2026 at 07:29, 4 months 19 days ago Financial year 2025: ElringKlinger enhances profitability while advancing its transformation ElringKlinger AG reports enhanced profitability and progress in transformation during the financial year 2025, with organic revenue growth and increased adjusted EBIT margin. Guidance for 2026 includes slight revenue growth and improved EBIT margin Profitability Transformation Organic Revenue Growth ElringKlinger AG Financial Year 2025
PRESS RELEASE published on 03/26/2026 at 07:29, 4 months 19 days ago DEUTZ generates growth and achieves one of the highest profits in its recent history despite challenging market conditions in 2025 DEUTZ achieves significant growth and high profits in 2025 despite challenging market conditions. Strategic transformation boosts revenue and profitability. New organizational structure aims for 2030 targets Transformation Growth 2025 Profits DEUTZ
PRESS RELEASE published on 03/26/2026 at 07:27, 4 months 19 days ago Delivery Hero reports adj EBITDA up 30% in 2025, as Quick Commerce and key markets gain momentum Delivery Hero SE reports 30% increase in adj EBITDA for 2025, showcasing growth and profitability. Strategic review and agreement for Taiwan sale Delivery Hero Strategic Review 2025 Results Adj EBITDA Taiwan Sale
PRESS RELEASE published on 03/26/2026 at 07:11, 4 months 19 days ago Berentzen-Gruppe Aktiengesellschaft publishes its 2025 Annual Report – Berentzen Group achieves significant consolidated profit Berentzen-Gruppe Aktiengesellschaft publishes its 2025 Annual Report with a significant consolidated profit of EUR 2.4 million. Forecast for the 2026 financial year presented Dividend Financial Forecast Consolidated Profit Berentzen-Gruppe Aktiengesellschaft 2025 Annual Report
PRESS RELEASE published on 03/26/2026 at 07:07, 4 months 19 days ago Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026 Heidelberg Pharma AG reports financial figures, business performance in 2025, and outlook for 2026, including CEO appointment, cost-cutting program, and extended cash runway. Fast Track designation for HDP-101 by FDA Financial Figures Outlook Business Performance Heidelberg Pharma Fast Track Designation
Published on 08/14/2026 at 20:05, 38 minutes ago GeoVolt Power Corp. and Orovada Lithium Project Update
Published on 08/14/2026 at 16:55, 3 hours 48 minutes ago SLAM Reports 1.19% Copper Equivalent Over 24.6 Metres in Hole GW26-29 From the Goodwin Copper-Nickel-Cobalt Project
Published on 08/14/2026 at 13:30, 7 hours 13 minutes ago Digi Power X Reports Second Quarter 2026 Financial Results and Provides Operational Update and 2027 Outlook
Published on 08/14/2026 at 13:15, 7 hours 28 minutes ago Mako Mining Reports Q2 2026 Financial Results, Including Adjusted EBITDA(1) of US$31.7 Million and EPS of US$0.16/Share
Published on 08/14/2026 at 13:10, 7 hours 33 minutes ago SouthGobi Announces Second Quarter 2026 Unaudited Financial and Operating Results
Published on 08/14/2026 at 18:15, 2 hours 28 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/14/2026 at 16:05, 4 hours 38 minutes ago GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON
Published on 08/14/2026 at 15:02, 5 hours 40 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/10/2026 at 18:00, 4 days 2 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 4 days 8 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 4 days 9 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 4 days 11 hours ago Number of shares and voting rights - July 2026 (In French only)